Merck slims diabetes lineup

Share this article:
Merck slims diabetes lineup
Merck slims diabetes lineup

Merck is cutting Juvisync from its diabetes lineup. Philly.com reports that the drug maker is ending distribution of its diabetes-cholesterol mix of sitgaliptin/simvastain tablet in the US and Puerto Rico.

The company's R&D chief Roger Perlmutter has said he is dedicated to keeping the company focused on drugs that work and drugs that sell. “This did not sell,” notes Philly.com.

Launched in 2011, the product was designed to offer something different in the metabolics space: the only pill packing a DPP-IV inhibitor (Januvia) and, for diabetics who need its lipid-lowering ability, a statin (Zocor).

At the time, neither DPP-IV Onglyza, from Bristol-Myers Squibb/AstraZeneca, nor rival Tradjenta, from Boehringer Ingelheim/Eli Lilly, had such a pairing in their lineups, and neither does today.

Since then, Takeda launched a DPP-IV, Nesina, and two combination pills. Oseni integrates the active ingredient in Nesina with pioglitazone, making it the first DPP-IV + TZD combo pill. The other, Kazano, combined Nesina with metformin, the widely used anti-diabetes medication.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.